At the 2025 ASH Annual Meeting and Exposition, researchers presented new findings that may meaningfully affect how patients ...

As a child Andrew Ochieng survived the world's second deadliest parasite. Today he is working to stop this little-known ...

Standard-of-care treatment with Janus kinase inhibitor monotherapy improves splenomegaly and symptom burden but provides ...

New trials reveal INCA033989 shows promise for treating CALR exon 9-mutated myelofibrosis, demonstrating efficacy and tolerability in patients.

For years, Mary considered herself pretty active. She used to play raquetball, swim, and participated in whitewater rafting down North California's rivers. Even when she wasn’t outdoors, she was busy ...

A 74-year-old Red Lion man died Dec. 6 at WellSpan York Hospital, a week after a single-vehicle crash caused injuries that ...

Red Lion resident Dennis A. Stouch initially declined medical treatment at the scene of the crash around 10 a.m. on Nov. 29.

Data were shared at the 67th Annual Meeting of the American Society of Hematology (ASH) ORLANDO, Fla.--(BUSINESS WIRE)--December 8, 2025-- Opna Bio, ...

Andhra Pradesh is on high alert after eight people have died from Scrub Typhus virus. Symptoms of scrub typhus usually begin ...

Early ASH 2025 data shows Incyte's INCA033989 delivers spleen, anemia and symptom improvements in mutCALR myelofibrosis.

AJ1-11095 is a first-in-class Type II JAK2 inhibitor currently in a Phase 1 study for the treatment of patients with ...

The novel radiotracer ¹⁸F-FAPI-RGD in PET/CT scans shows potential for diagnosing ILD in connective tissue disease patients by highlighting fibroblast activation and tissue remodeling. Patients with ...